Referencia número: HY-N0431

Astragaloside IV

Name: Astragaloside IV
Brand: MedChemExpress
SKU: HY-N0431
Price: 42.00 USD
Availability: InStock
Rating: 5 (43 reviews)

43 Cited Publications

Revisión del cliente

Based on 43 publication(s) in Google Scholar

Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 99.93%
No. CAS: 84687-43-4
Fòrmula: C₄₁H₆₈O₁₄
Peso molecular:784.97

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Astragaloside IV Chemical Structure

No. CAS: 84687-43-4

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (43)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

^[4]

MMP-2

MMP-9

ERK1

ERK2

JNK

Ver todos los productos específicos de isoformas MMP :

Ver todos los productos específicos de isoformas ERK :

Ver todos los productos específicos de isoformas JNK :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	>100 μM Compound: 20	Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24974349]
Vero	CC₅₀	>1000 μg/mL Compound: Astragaloside-IV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 37159959]
Vero	EC₅₀	1.56 μg/mL Compound: Astragaloside-IV	Antiviral activity against Dengue virus 2 infected in African green monkey Vero cells assessed as suppression of viral replication Antiviral activity against Dengue virus 2 infected in African green monkey Vero cells assessed as suppression of viral replication	[PMID: 37159959]

In Vitro

Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin^[2]. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression^[1].
In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 84687-43-4
Appearance Solid
Peso molecular 784.97
Fòrmula C₄₁H₆₈O₁₄
Color White to off-white
SMILES

O[C@H]1[C@H](O)[C@@H](O)[C@]([H])(O[C@@H]2C(C)(C)[C@@]([C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@]4([H])[C@@]56CC[C@@]7(C)[C@@]4(C)C[C@H](O)[C@]7([H])[C@]8(C)O[C@H](C(C)(O)C)CC8)([H])[C@]5(C6)CC2)OC1
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (43)

All RT-PCRWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Exploration

A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors. [Abstract]

2025 Dec 18;5(6):20240396. PMID: 41476656
J Nanobiotechnology

Astragaloside IV- loaded biomimetic nanoparticles target IκBα to regulate neutrophil extracellular trap formation for sepsis therapy. [Abstract]

2025 Feb 28;23(1):155. PMID: 40022068
Phytomedicine

Astragaloside IV directly targets PPP1R14B to sensitize prostate cancer to anti-PD-1 immunotherapy by remodeling the CX3CL1/CD8+ T cell axis. [Abstract]

2026 Jun:155:158158. PMID: 41950731
Phytomedicine

Astragaloside IV remodels gastric inflammation-cancer transformation by modulating the CXCL5-CXCR2 axis-mediated epithelial-mesenchymal transition. [Abstract]

2026 Jun:155:158081. PMID: 41861684
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2. [Abstract]

2024 Nov:134:155991. PMID: 39217653
Int J Mol Med

Astragaloside IV targets TUBB4B to inhibit proliferation and promote apoptosis of pituitary tumor cells via the STMN1/ERK pathway. [Abstract]

2026 Jun;57(6):151. PMID: 41930558
Phytother Res

Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia-Reperfusion Injury via the TLR4/MyD88/NF-κB p65 Pathway in Rats. [Abstract]

2025 Oct;39(10):4744-4765. PMID: 40907985
Phytother Res

Astragaloside IV Relieves Central Sensitization by Regulating Astrocytic ROS/NF-κB Nuclear Translocation Signaling in Chronic Migraine Male Rats. [Abstract]

2025 Mar;39(3):1438-1452. PMID: 39801364
Am J Chin Med

Astragaloside IV Ameliorates Diabetic Kidney Disease via Inhibiting MAPK Pathway and Alleviating Metabolic Dysregulation. [Abstract]

2026;54(4):1281-1307. PMID: 42289390
Chin Med

Therapeutic potential of Sheng-Xian-Tang in doxorubicin-induced chronic heart failure by regulation of phenylalanine metabolism disruption. [Abstract]

2026 Jan 12;21(1):29. PMID: 41527105
Biochem Pharmacol

2026 Jul 23;253(Pt 1):118285. PMID: 42492764
Drug Des Devel Ther

Astragaloside IV Promotes Osteogenic Differentiation of Periodontal Ligament Stem Cells via Activating PI3K/AKT/eNOS/NO Signaling Pathway: In vitro and in vivo Study. [Abstract]

2025 Jul 16:19:6073-6088. PMID: 40687900
Eur J Pharmacol

Daidzein ameliorates LPS-induced hepatocyte injury by inhibiting inflammation and oxidative stress. [Abstract]

2020 Oct 15:885:173399. PMID: 32712091
Int Immunopharmacol

Astragaloside IV alleviates ulcerative colitis via gut microbiota - butyrate metabolism axis to reshape Th17/Treg balance. [Abstract]

2026 Feb 15:171:116135. PMID: 41483616
Int Immunopharmacol

Astragaloside IV ameliorates atherosclerosis by targeting TAK1 to suppress endothelial cell proinflammatory activation. [Abstract]

2025 Jan 27:146:113842. PMID: 39706043
Int Immunopharmacol

Protective effect of taraxasterol on ischemia/reperfusion-induced acute kidney injury via inhibition of oxidative stress, inflammation, and apoptosis. [Abstract]

2020 Dec;89(Pt A):107169. PMID: 33183976
Mol Neurobiol

Potential Therapeutic Effects of Astragaloside IV in Parkinson's Disease Models via Modulation of α-syn-γH2AX-STING-IFN-I Axis. [Abstract]

2025 Nov 7;63(1):11. PMID: 41204052
Front Pharmacol

Astragaloside IV Inhibits Triglyceride Accumulation in Insulin-Resistant HepG2 Cells via AMPK-Induced SREBP-1c Phosphorylation. [Abstract]

2018 Apr 16:9:345. PMID: 29713279

Astragaloside IV purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Apr 16:9:345. [Abstract]

AMP-activated protein kinase activation by AST inhibits the expression of sterol regulatory element binding protein-1c (SREBP-1c) and SREBP-1c related genes. AST promotes AMPKa1 mRNA expression, AMPKa2 mRNA expression, and suppresses the expression of SREBP-1c, and its downstream genes FAS, ACC1, and also AMPK downstream gene SCD1.

Astragaloside IV purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Apr 16:9:345. [Abstract]

AMP-activated protein kinase (AMPK) activation by AST blunts dysfunction of lipid metabolism and insulin resistance in HepG2 cells. Representative bands of SREBP-1c nuclear protein and cytoplasmic proteins are visualized in the immunoblotting assay.
Mol Med Rep

Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway. [Abstract]

2026 Jan;33(1):38. PMID: 41235672
J Mol Med (Berl)

Astragaloside IV inhibits the progression of hypertensive heart disease via the RXRA/PPARG/SIRT3 axis. [Abstract]

2025 Dec 16;104(1):6. PMID: 41402523
Sci Rep

Astragaloside IV attenuates cadmium induced nephrotoxicity in rats by activating Nrf2. [Abstract]

2025 Jan 15;15(1):2028. PMID: 39815001
Cell Signal

Astragaloside IV enhances autophagy to suppress endoplasmic reticulum stress and pyroptosis after spinal cord injury. [Abstract]

2026 Sep:145:112571. PMID: 42086120
J Inflamm Res

Astragaloside IV Attenuates Angiotensin II-Induced Inflammatory Responses in Endothelial Cells: Involvement of Mitochondria. [Abstract]

2025 Mar 17:18:3951-3967. PMID: 40125084
BMC Cancer

Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1. [Abstract]

2024 Jun 4;24(1):682. PMID: 38835015
Funct Integr Genomics

Astragaloside IV suppresses the migration and EMT progression of cervical cancer cells by inhibiting macrophage M2 polarization through TGFβ/Smad2/3 signaling. [Abstract]

2023 Apr 21;23(2):133. PMID: 37081108

Astragaloside IV purchased from MedChemExpress. Usage Cited in: Funct Integr Genomics. 2023 Apr 21;23(2):133. [Abstract]

Astragaloside IV (AS-IV; 20, 40 μM; 24 h) reverses the conditioned medium (CM) downregulated expression of E-cadherin and the conditioned medium (CM) upregulated expression of α-SMA in CC cells (the CM from M2 macrophages).

Astragaloside IV purchased from MedChemExpress. Usage Cited in: Funct Integr Genomics. 2023 Apr 21;23(2):133. [Abstract]

Astragaloside IV (AS-IV; 60, 80, 160 μM; 48 h) signifcantly inhibits the viability of M2 macrophages.
Neurotoxicology

Astragaloside IV attenuates cisplatin-induced ototoxicity by preserving mitochondrial function and activating the Nrf2 signaling pathway. [Abstract]

2026 May:114:103451. PMID: 41990879
Chin J Integr Med

Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 Pathway. [Abstract]

2025 May;31(5):422-433. PMID: 39039342
Vet Microbiol

AS-IV exhibits anti-SADS-CoV effects through the inhibition of the MAPK/JNK signaling pathway mediated by the S1 protein. [Abstract]

2026 Feb:313:110858. PMID: 41477941
J Mol Histol

Protocol for the purification and culture of primary retinal ganglion cells and development of common pathological models. [Abstract]

2025 Aug 8;56(4):260. PMID: 40779178
Hereditas

Astragaloside IV regulates FOXM1 deubiquitination to ameliorate trophoblast damage caused by high glucose. [Abstract]

2025 Jun 13;162(1):104. PMID: 40514721
Methods Protoc

Development of a 3D Perfused In Vitro System to Assess Proangiogenic Properties of Compounds. [Abstract]

2023 Dec 9;6(6):119. PMID: 38133139
Exp Ther Med

Astragaloside IV alleviates the symptoms of experimental ulcerative colitis in vitro and in vivo. [Abstract]

2019 Oct;18(4):2877-2884. PMID: 31572532
In Vitro Cell Dev Biol Anim

Astragaloside promotes the secretion of MSC-derived exosomal miR-146a-5p by regulating TRAF6/NF-κB pathway to attenuate inflammation in high glucose-impaired endothelial cells. [Abstract]

2025 Jan;61(1):93-106. PMID: 39441504
Eur J Histochem

Astragaloside IV inhibits nasopharyngeal carcinoma progression by inhibiting SATB2/Wnt/PD-L1 pathway and enhancing the killing activity of T cells. [Abstract]

2026 Apr 20;70(2). PMID: 42206678
Eur J Histochem

Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment. [Abstract]

2024 Oct 23;68(4). PMID: 39440587
SSRN

2026 Apr 14.
Biomed Pharmacother

Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1/PGC1α /Nrf1 signaling pathway. [Abstract]

2024 Aug:177:117008. PMID: 38901196
Heliyon

Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway. [Abstract]

2024 May 9;10(10):e30984. PMID: 38803993
Heliyon

Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation. [Abstract]

2023 Apr 11;9(4):e15436. PMID: 37113780
Research Square Preprint

2022 Jun.
Bioengineered

Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2. [Abstract]

2022 Apr;13(4):8240-8254. PMID: 35302431
Research Square Preprint

2021 Aug.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (127.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2739 mL

6.3697 mL

12.7393 mL

5 mM

0.2548 mL

1.2739 mL

2.5479 mL

10 mM

0.1274 mL

0.6370 mL

1.2739 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (3.18 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 8 mg/mL (10.19 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Water

Solubility: 8 mg/mL (10.19 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Kinase Assay^[4]

Briefly, MDA-MB-231 cells treated as indicated or tumor tissues are harvested and lysed in Mg²⁺ lysis buffer containing 50 mM Tris (pH 7.5), 10 mM MgCl₂, 0.5 M NaCl, and protease inhibitor cocktail. Equal amounts of lysates are incubated with PAK-PBD beads at 4°C for 1 h. PAK-PBD beads are pelleted by centrifugation and washed with ish buffer containing 25 mM Tris (pH 7.5), 30 mM MgCl₂, 40 mM NaCl. Active Rac1 is detected by western blotting.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Cell viability is determined by CCK-8 assay. To be brief, cultured NSCLC cells are seeded into 96-well plates at the density of 4×10⁴ (cells/well). Then 10 µL⁄well CCK8 solution is added and incubated in dark at 37°C for another 2 h. The absorbance is determined with the wavelength of 490 nm.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Transient cerebral ischemia and reperfusion is prepared by BCCAO, as BCCAO is considered an ideal model to study transient cerebral ischemia and reperfusion injury-mediated inflammatory response. Mice are randomLy divided into the Sham, Model, Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) treatment groups. The Astragaloside IV treatment groups are intragastrically administered 7 days before the surgery and terminated on the day of sacrifice. On the day of the surgery, Astragaloside IV is administrated 2 h prior to ischemia. The Sham-operated and Model groups are treated with distilled water. After the mice are anesthetized with an intraperitoneal injection of chloral hydrate (350 mg/kg), the bilateral common carotid arteries are exposed and carefully separated with a small ventral neck incision and occluded twice (20 min each) with ligated surgical silk as described previously with minor modifications. There is a 10 min reperfusion period between the two occlusion periods (ischemia 20 min − reperfusion 10 min − ischemia 20 min). Sham-operated mice are subjected to the same surgical operation without the surgical silk ligation. Mouse body temperature is maintained at 37±0.5°C during the surgery with heating equipment until recovery from the anesthesia.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Li M, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. Neurosci Lett. 2016 Dec 20. pii: S0304-3940(16)30994- [Content Brief]

[2]. He CS, et al. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221-1229. Epub 2016 Dec 14. [Content Brief]

[3]. Liu L, et al. [Protective effect of astragaloside IV against acute liver failure in experimental mice]. Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):772-777 [Content Brief]

[4]. Jiang K, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2016 Dec 5;42:195-20 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2739 mL	6.3697 mL	12.7393 mL	31.8484 mL
	5 mM	0.2548 mL	1.2739 mL	2.5479 mL	6.3697 mL
	10 mM	0.1274 mL	0.6370 mL	1.2739 mL	3.1848 mL
	15 mM	0.0849 mL	0.4246 mL	0.8493 mL	2.1232 mL
	20 mM	0.0637 mL	0.3185 mL	0.6370 mL	1.5924 mL
	25 mM	0.0510 mL	0.2548 mL	0.5096 mL	1.2739 mL
	30 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0616 mL
	40 mM	0.0318 mL	0.1592 mL	0.3185 mL	0.7962 mL
	50 mM	0.0255 mL	0.1274 mL	0.2548 mL	0.6370 mL
	60 mM	0.0212 mL	0.1062 mL	0.2123 mL	0.5308 mL
	80 mM	0.0159 mL	0.0796 mL	0.1592 mL	0.3981 mL
	100 mM	0.0127 mL	0.0637 mL	0.1274 mL	0.3185 mL

Bioz

Keywords

Astragaloside IV

43 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Astragaloside IV

Publications Citing Use of MedChemExpress (MCE) Astragaloside IV

Ver todos los productos específicos de isoformas MMP

Ver todos los productos específicos de isoformas ERK

Ver todos los productos específicos de isoformas JNK